22nd November 2011
Health Information Announces Investment from MVM Life Science Partners
Health Information, the dominant provider of point of dispensing messaging in the UK, announces that it has secured a first round of funding from MVM Life Sciences LLP.
Read this article
15th September 2011
Horizon Discovery Announces £11.3 Million Fundraising
Horizon Discovery, a leading provider of research tools to support the development of personalised medicines, has announced that it has completed a second closing of its Series C funding round, realising a cumulative total of £11.3m, with MVM Life Sciences LLP leading the second closing.
Read this article
28th July 2011
AccuVein Secures $22.5 million Series B Financing through MVM Life Science Partners and Bessemer Venture Partners
AccuVein Inc., a global leader in medical imaging technology and the creator of the AV300, the world’s first hand-held, non-contact vein illumination device, has announced that it has secured $22.5 million in a Series B financing.
Read this article
12th July 2011
Tarsa Therapeutics Advances its Oral Calcitonin for the Treatment and Prevention of Postmenopausal Osteoporosis
Tarsa Therapeutics has announced that the positive Phase III data from the registration trial of its oral calcitonin drug has been accepted for an oral presentation at the ASBMR Annual Meeting, patient enrolment is complete in the Phase II proof-of-concept prevention study in 120 postmenopausal women and Tarsa has closed an additional financing of $24.5 million.
Read this article
28th June 2011
Argenta Signs Integrated Services Agreement with Pulmagen Therapeutics
Galapagos NV (Euronext: GLPG) announced today that service division Argenta has signed a subcontracting agreement with Pulmagen Therapeutics Limited to perform integrated services on two respiratory projects.
Read this article
News Archive
Last 5 Articles | Next 5 Articles
12th October 2009Heptares Therapeutics Announces Agreement with Novartis Option Fund
Welwyn Garden City, UK. Heptares Therapeutics Ltd, the drug discovery company focused on G-protein-coupled receptor (GPCR) targets, announced today that it has entered into an option agreement with the Novartis Option Fund under which Heptares will apply its proprietary StaR™ technology to generate novel drug leads against a nominated, unspecified GPCR target of interest to Novartis. The agreement includes upfront and potential milestone payments to Heptares totaling up to $200 million plus royalties. Full financial terms were not disclosed.
StaR technology enables GPCRs, normally membrane-bound, to be worked on in solution, allowing the use of structure-based drug discovery technologies and the discovery of novel drugs addressing this important set of targets. Heptares is deploying this technology principally to generate small molecule drugs against currently difficult or intractable GPCR targets in several disease areas.
Under the terms of the agreement with the Novartis Option Fund, Heptares will apply its StaR technology to a target identified by Novartis and drive a drug discovery programme against that target.
“This is an excellent early deal for Heptares, endorsing our StaR technology and further strengthening our financial position,” said Malcolm Weir, CEO of Heptares Therapeutics. “The deal with the Novartis Option Fund demonstrates confidence that our approach can unlock the potential of GCPR targets and forms a solid foundation for other partnerships with leading pharmaceutical companies.”
“The potential of GPCRs as targets for drug discovery is well recognized, but it has always been a challenge to gain structural information on GPCRs,” said Anja Koenig for the Novartis Option Fund. “We believe that the power of Heptares’ technology to resolve GPCR structures and their expertise in small molecule chemistry will lead to rapid progress in the drug discovery programme against Novartis’ nominated target.”
The Novartis Option Fund invested £7 million in Heptares’ £21 million fundraising announced in February 2009 in a syndicate with MVM Life Science Partners and Clarus Ventures.
| Associated Links Visit Heptares Therapeutics Limited |
Downloads Full Press Release |